Anti-IL-6 Ab, such as siltuximab, and anti-IL-6R Ab, such as tocilizumab, have been reported to inhibit both classical signaling and trans-signaling, and their effects have been investigated in various cancer types in preclinical and early-stage clinical studies (Jones and Jenkins, 2018; Rose-John et al., 2023). This evidence concerns the gene IL6 and cancer.